| HOME >> BIOLOGY >> TECHNOLOGY |
COLORADO SPRINGS, Colo. and REYKJAVIK, Iceland, Dec. 3 /PRNewswire/ -- HemoGenix(R) and ORF Genetics announce the collaboration and implementation of biorisk-free, green-source growth factors and cytokines for use in all HALO(R) Assay Kits and HALO(R) Contract Research Services where the response of human blood-forming cells is detected.
ORF Genetics produces a large number of growth factors and cytokines using barley seed as the production host. Their Orfeus(TM) Expression System, comprised of a barley endosperm expression background, gf22 expression cassette, HEKLAgro(TM) cultivation technology, and the production of isogenic lines for seed banking, makes this the most efficient and "green" production of human growth factors and cytokines for R&D medical research, cellular therapy, regenerative medicine, cosmetics and biopharma. ORF Genetics products are free of contaminants for bacterial, viral and prion components; non- pyrogenic; endotoxin-free; and perfectly safe according to FDA guidelines.
Through close collaboration, HemoGenix(R) has tested the growth factors and cytokines produced by ORF Genetics and found them to produce similar, if not superior, potency for growth of human bone marrow, cord blood and peripheral blood cells using its HALO(R) ATP-based, bioluminescence proliferation/cytotoxicity assay platform. The growth factors and cytokines needed to stimulate and detect various blood-forming stem and progenitor cell populations will now be incorporated into the complete line of HALO(R) Assay Kits produced by HemoGenix(R). This is particularly important for the family of HALO(R) quality control and potency assays used to ensure "stem cell quality" and "stem cell potency" for release of stem cell products, particularly umbilical cord blood, prior to transplantation into patients.
HemoGenix(R) will also incorporate ORF Genetics growth factors and
cytokines into its HALO(R) Hemotoxici
'/>"/>
| SOURCE HemoGenix, Inc Copyright©2008 PR Newswire. All rights reserved |